How many drugs treat Minor Bacterial Skin Infections?

Drug Landscape tracks 7 marketed treatments for Minor Bacterial Skin Infections (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/minor-bacterial-skin-infections.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Minor Bacterial Skin Infections — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Minor Bacterial Skin Infections (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Minor Bacterial Skin Infections, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Silvadene	Silver Sulfadiazine	Pfizer	sulfonamide antimicrobial	bacterial cell membrane and cell wall	1973-01-01
Cortisporin	POLYMYXIN B	Pfizer	Polymyxin-class Antibacterial		1957-01-01
Cortisporin	NEOMYCIN	Pfizer	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 1	1957-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Cortisporin	BACITRACIN	Pfizer	bacitracin	Tyrosine-protein kinase Lck	1948-01-01
Sulfadiazine	SULFADIAZINE	Eli Lilly	Sulfonamide Antibacterial [EPC]	5-hydroxytryptamine receptor 2A	1941-01-01
Cortisol	Cortisol	University of Zurich		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 4 drugs in Minor Bacterial Skin Infections
· 3 drugs in Minor Bacterial Skin Infections
Eli Lilly · 1 drug in Minor Bacterial Skin Infections
Generic (originally Merck/Upjohn) · 1 drug in Minor Bacterial Skin Infections
University of Zurich · 1 drug in Minor Bacterial Skin Infections

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Minor Bacterial Skin Infections:

Cite this brief

Drug Landscape (2026). Minor Bacterial Skin Infections — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/minor-bacterial-skin-infections. Accessed 2026-06-10.

Minor Bacterial Skin Infections full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing